Skip to content
Catalyst

PapersPMID:38264278

Effects and safety of Ginkgo biloba on blood metabolism in type 2 diabetes mellitus: a systematic review and meta-analysis.

Frontiers in endocrinology2023The record ↗

findings
6
compound
1
endpoints
6
no difference found
5
PMID:38264278
  1. Finding, moderate evidencelowersHaematocrit
  2. Finding, moderate evidenceno difference foundTotal cholesterol (TC)
  3. Finding, moderate evidenceno difference foundTriglycerides
  4. Finding, moderate evidenceno difference foundLDL cholesterol
  5. Finding, moderate evidenceno difference foundHDL cholesterol
  6. Finding, moderate evidenceno difference foundGlycated haemoglobin (HbA1c)
Study, every finding
meta-analysis

What moved

How to read these marks →
  • Decreases haematocrit

    moderate

    “Five articles reported hematocrit (Hct), and meta-analysis results showed that GKB also had lower Hct than control (SMD=-0.60, 95%CI [-0.97, -0.24], P<0.01).”
    Effect
    −0.6 standardised mean difference, 95% CI −0.97 to −0.24
    Population
    Patients with type 2 diabetes mellitus; five pooled randomised trials, most adding the extract to metformin against metformin alone

What did not

  • No detected effect on total cholesterol (TC)

    moderate

    “Upon total cholesterol (TC)(mmol/L) comparison, GKB showed no difference compared to the control (SMD=-0.37, 95%CI [-0.84, 0.09], P=0.11).”
    Effect
    −0.37 standardised mean difference, 95% CI −0.84 to 0.09
    Population
    Patients with type 2 diabetes mellitus; pooled randomised trials, most adding the extract to metformin against metformin alone
  • No detected effect on triglycerides

    moderate

    “Pooled analysis of triglyceride (TG) (mmol/L) showed no difference between GKB and control (SMD=-0.60, 95%CI [-1.25, 0.04], P=0.06).”
    Effect
    −0.6 standardised mean difference, 95% CI −1.25 to 0.04
    Population
    Patients with type 2 diabetes mellitus; pooled randomised trials, most adding the extract to metformin against metformin alone
  • “Both low-density lipoprotein (LDL) (mmol/L) (SMD=-0.34, 95%CI [-0.73, 0.04], P=0.08) and high-density lipoprotein (HDL) (mmol/L) (SMD=0.31, 95%CI [-0.60, 1.22], P=0.51) showed no difference compared to the GKB and control groups.”
    • No detected effect on LDL cholesterol

      moderate

      Effect
      −0.34 standardised mean difference, 95% CI −0.73 to 0.04
      Population
      Patients with type 2 diabetes mellitus; pooled randomised trials, most adding the extract to metformin against metformin alone
    • No detected effect on HDL cholesterol

      moderate

      Effect
      0.31 standardised mean difference, 95% CI −0.6 to 1.22
      Population
      Patients with type 2 diabetes mellitus; pooled randomised trials, most adding the extract to metformin against metformin alone
  • No detected effect on glycated haemoglobin (HbA1c)

    moderate

    “Meta-analysis of both hemoglobin A1c (HbA1c)(%) (SMD=-0.15, 95%CI [-0.54, 0.24] P=0.44) and fasting serum glucose (FSG)(mmol/L) (SMD=0.07, 95%CI [-0.75, 0.88] P=0.87) showed no difference between the GKB and control.”
    Effect
    −0.15 standardised mean difference, 95% CI −0.54 to 0.24
    Population
    Patients with type 2 diabetes mellitus; pooled randomised trials, most adding the extract to metformin against metformin alone

Study record

Design
meta-analysis
Species
human
Population
adults with type 2 diabetes mellitus
Participants
1,573
Comparator
an active treatment / no treatment / placebo
Duration
not reported
Endpoints measured
12